Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Caroline Ogwang; Muhammed Afolabi; Domtila Kimani; Ya Jankey Jagne; Susanne H. Sheehy; Carly M. Bliss; Christopher J.A. Duncan; Katharine A. Collins; Miguel A. Garcia Knight; Eva Kimani; Nicholas A. Anagnostou; Eleanor Berrie; Sarah Moyle; Sarah C. Gilbert; Alexandra J. Spencer; Peninah Soipei; Jenny Mueller; Joseph Okebe; Stefano Colloca; Riccardo Cortese; Nicola K. Viebig; Rachel Roberts; Katherine Gantlett; Alison M. Lawrie; Alfredo Nicosia; Egeruan B. Imoukhuede; Philip Bejon; Britta Urban; Katie L. Flanagan; Katie J. Ewer; Roma Chilengi; Adrian V.S. Hill; Kalifa Bojang

doi:10.1371/journal.pone.0057726

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Caroline Ogwang, Muhammed Afolabi, Domtila Kimani, Ya Jankey Jagne, Susanne H. Sheehy, Carly M. Bliss, Christopher J.A. Duncan, Katharine A. Collins, Miguel A. Garcia Knight, Eva Kimani, Nicholas A. Anagnostou, Eleanor Berrie, Sarah Moyle, Sarah C. Gilbert, Alexandra J. Spencer, Peninah Soipei, Jenny Mueller, Joseph Okebe, Stefano Colloca, Riccardo CorteseNicola K. Viebig, Rachel Roberts, Katherine Gantlett, Alison M. Lawrie, Alfredo Nicosia, Egeruan B. Imoukhuede, Philip Bejon, Britta Urban, Katie L. Flanagan, Katie J. Ewer, Roma Chilengi, Adrian V.S. Hill, Kalifa Bojang

Tropical Disease Biology

Research output: Contribution to journal › Article › peer-review

65 Citations (Scopus)

Abstract

BACKGROUND

Heterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine candidate, capable of inducing sterile protection in malaria naïve adults following controlled human malaria infection (CHMI).

METHODOLOGY

We conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission patterns.

RESULTS

ChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median >1300 SFU/million PBMC).

CONCLUSIONS

ChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field are now warranted.

Original language	English
Article number	e57726
Pages (from-to)	e57726
Journal	PLoS ONE
Volume	8
Issue number	3
DOIs	https://doi.org/10.1371/journal.pone.0057726
Publication status	Published - 19 Mar 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pone.0057726Licence: CC BY

PLoS ONE 8 3 e57726Final published version, 845 KBLicence: CC BY

Cite this

Ogwang, C., Afolabi, M., Kimani, D., Jagne, Y. J., Sheehy, S. H., Bliss, C. M., Duncan, C. J. A., Collins, K. A., Garcia Knight, M. A., Kimani, E., Anagnostou, N. A., Berrie, E., Moyle, S., Gilbert, S. C., Spencer, A. J., Soipei, P., Mueller, J., Okebe, J., Colloca, S., ... Bojang, K. (2013). Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. PLoS ONE, 8(3), e57726. Article e57726. https://doi.org/10.1371/journal.pone.0057726

@article{cefb1e784def4ce6971cfa3da2f1260a,

title = "Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.",

abstract = "BACKGROUNDHeterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine candidate, capable of inducing sterile protection in malaria na{\"i}ve adults following controlled human malaria infection (CHMI).METHODOLOGYWe conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission patterns.RESULTSChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median >1300 SFU/million PBMC).CONCLUSIONSChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field are now warranted.",

author = "Caroline Ogwang and Muhammed Afolabi and Domtila Kimani and Jagne, \{Ya Jankey\} and Sheehy, \{Susanne H.\} and Bliss, \{Carly M.\} and Duncan, \{Christopher J.A.\} and Collins, \{Katharine A.\} and \{Garcia Knight\}, \{Miguel A.\} and Eva Kimani and Anagnostou, \{Nicholas A.\} and Eleanor Berrie and Sarah Moyle and Gilbert, \{Sarah C.\} and Spencer, \{Alexandra J.\} and Peninah Soipei and Jenny Mueller and Joseph Okebe and Stefano Colloca and Riccardo Cortese and Viebig, \{Nicola K.\} and Rachel Roberts and Katherine Gantlett and Lawrie, \{Alison M.\} and Alfredo Nicosia and Imoukhuede, \{Egeruan B.\} and Philip Bejon and Britta Urban and Flanagan, \{Katie L.\} and Ewer, \{Katie J.\} and Roma Chilengi and Hill, \{Adrian V.S.\} and Kalifa Bojang",

year = "2013",

month = mar,

day = "19",

doi = "10.1371/journal.pone.0057726",

language = "English",

volume = "8",

pages = "e57726",

journal = "PLoS ONE",

publisher = "Public Library of Science",

number = "3",

}

Ogwang, C, Afolabi, M, Kimani, D, Jagne, YJ, Sheehy, SH, Bliss, CM, Duncan, CJA, Collins, KA, Garcia Knight, MA, Kimani, E, Anagnostou, NA, Berrie, E, Moyle, S, Gilbert, SC, Spencer, AJ, Soipei, P, Mueller, J, Okebe, J, Colloca, S, Cortese, R, Viebig, NK, Roberts, R, Gantlett, K, Lawrie, AM, Nicosia, A, Imoukhuede, EB, Bejon, P, Urban, B, Flanagan, KL, Ewer, KJ, Chilengi, R, Hill, AVS & Bojang, K 2013, 'Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.', PLoS ONE, vol. 8, no. 3, e57726, pp. e57726. https://doi.org/10.1371/journal.pone.0057726

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults. / Ogwang, Caroline; Afolabi, Muhammed; Kimani, Domtila et al.
In: PLoS ONE, Vol. 8, No. 3, e57726, 19.03.2013, p. e57726.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

AU - Ogwang, Caroline

AU - Afolabi, Muhammed

AU - Kimani, Domtila

AU - Jagne, Ya Jankey

AU - Sheehy, Susanne H.

AU - Bliss, Carly M.

AU - Duncan, Christopher J.A.

AU - Collins, Katharine A.

AU - Garcia Knight, Miguel A.

AU - Kimani, Eva

AU - Anagnostou, Nicholas A.

AU - Berrie, Eleanor

AU - Moyle, Sarah

AU - Gilbert, Sarah C.

AU - Spencer, Alexandra J.

AU - Soipei, Peninah

AU - Mueller, Jenny

AU - Okebe, Joseph

AU - Colloca, Stefano

AU - Cortese, Riccardo

AU - Viebig, Nicola K.

AU - Roberts, Rachel

AU - Gantlett, Katherine

AU - Lawrie, Alison M.

AU - Nicosia, Alfredo

AU - Imoukhuede, Egeruan B.

AU - Bejon, Philip

AU - Urban, Britta

AU - Flanagan, Katie L.

AU - Ewer, Katie J.

AU - Chilengi, Roma

AU - Hill, Adrian V.S.

AU - Bojang, Kalifa

PY - 2013/3/19

Y1 - 2013/3/19

N2 - BACKGROUNDHeterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine candidate, capable of inducing sterile protection in malaria naïve adults following controlled human malaria infection (CHMI).METHODOLOGYWe conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission patterns.RESULTSChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median >1300 SFU/million PBMC).CONCLUSIONSChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field are now warranted.

AB - BACKGROUNDHeterologous prime boost immunization with chimpanzee adenovirus 63 (ChAd63) and Modified vaccinia Virus Ankara (MVA) vectored vaccines is a strategy recently shown to be capable of inducing strong cell mediated responses against several antigens from the malaria parasite. ChAd63-MVA expressing the Plasmodium falciparum pre-erythrocytic antigen ME-TRAP (multiple epitope string with thrombospondin-related adhesion protein) is a leading malaria vaccine candidate, capable of inducing sterile protection in malaria naïve adults following controlled human malaria infection (CHMI).METHODOLOGYWe conducted two Phase Ib dose escalation clinical trials assessing the safety and immunogenicity of ChAd63-MVA ME-TRAP in 46 healthy malaria exposed adults in two African countries with similar malaria transmission patterns.RESULTSChAd63-MVA ME-TRAP was shown to be safe and immunogenic, inducing high-level T cell responses (median >1300 SFU/million PBMC).CONCLUSIONSChAd63-MVA ME-TRAP is a safe and highly immunogenic vaccine regimen in adults with prior exposure to malaria. Further clinical trials to assess safety and immunogenicity in children and infants and protective efficacy in the field are now warranted.

U2 - 10.1371/journal.pone.0057726

DO - 10.1371/journal.pone.0057726

M3 - Article

VL - 8

SP - e57726

JO - PLoS ONE

JF - PLoS ONE

IS - 3

M1 - e57726

ER -

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this